Skip to main content
OpenTrials
Completed

NCT Number: NCT00472667

PROcalcitonin Reduce Antibiotic Treatments in Acute-Ill Patients (PRORATA)

The study is a prospective, randomized, controlled intervention trial conducted in 9 centers, comparing a conventional strategy versus a PCT-guided strategy to start or to discontinue antibiotics, in patients with suspected community or hospital- acquired infection.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Chu Bichat Claude Bernard

Paris, 75018, France

About this study

Clinical and laboratory signs are neither specific nor sensitive for diagnosis of sepsis in critically-ill patients. Because delaying antimicrobial therapy may be deleterious, broad-spectrum antibiotics are widely used in ICU -patients, even when they are not needed. In addition, only few well-designed studies concerning the duration of antibiotic treatment have been so far published. Consequently, many patients received antibiotics during the ICU stay. Many studies have shown that exposure to antibiotics, the so called "selection pressure" is an independent risk factor for acquisition of resistance in individual patients. Therefore, reducing antibiotic use is probably necessary to control antibiotic resistance. Many clinical studies have shown that procalcitonin (PCT) is able to distinguish the inflammatory response to infection from other types of inflammation and to distinguish bacterial from viral infections. Recent studies have shown that PCT guidance substantially and safely reduced antibiotic overuse in patients with lower respiratory tract infections. We aimed to evaluate the role of PCT in reducing the use of antibiotics in ICU adult patients. The study is a prospective, randomized, controlled intervention trial conducted in 9 centers, comparing a conventional strategy versus a PCT-guided strategy to start or to discontinue antibiotics, in patients with suspected community or hospital- acquired infection.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient hospitalised in the ICU
  • Bacterial infection suspected
  • At ICU admission the patient do not receive antibiotics or receive antibiotics for less than 24hours and an interval between admission and inclusion < 12 hours
  • During ICU stay, provided that the interval between the start of suspected infection and inclusion is < 12hours
  • Written inform consent from the patient or relatives. The consent may be obtained after the enrollment if the patient is not able to give consent and if there is no relatives

Exclusion criteria

  • Age < 18 years
  • Pregnancy
  • Patient expected to remain hospitalised in the ICU for less than 3 days
  • Neutropenia
  • Infection or presumed infection requiring prolonged antibiotic therapy (endocarditis,osteo-articular infection, mediastinitis, deep abscess, tuberculosis, pneumocystis pneumonia, toxoplasmosis).
  • Simplified Acute Physiology Score II at ICU admission (calculated during the first 12h)
  • Attending physician declining to use full life support.

Treatment and study plan

Procalcitonin guided strategy

Procedure

Procalcitonin guided strategy

Primary outcomes

  1. Exposition to antibiotics, defined by antibiotic-free days

    Time frame: assessed 28 days after inclusion

  2. Mortality

    Time frame: at Day 28 and Day 60

Secondary outcomes

  1. Consumption of antibiotics expressed as the Defined Daily Dose/1000 ICU-days

    Time frame: between D1 and D28

  2. The length of ICU and hospital stay

    Time frame: during the stay at the hospital

  3. The evolution of SOFA score parameters

    Time frame: between D1 and D28

  4. The number of mechanical ventilation-free days

    Time frame: at D28

  5. The acquisition cost of antibiotics

    Time frame: between D1 and D28

  6. The percentage of emerging multiresistant bacteria between D1 and D28, as assessed by microbiologic examination of all clinical samples.

    Time frame: between D1 and D28

  7. The percentages of relapses of infection

    Time frame: between D1 and D28

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Registry information

Official study title

Impact of Procalcitonin to Reduce Antibiotics Use in ICU Adults Patients

Acronym: PRORATA

Important dates

Study start
2007
Primary completion
2008
Study completion
2008
First posted
May 14, 2007
Registry last updated
Nov 25, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.